Data from the phase 3b STEP UP trial demonstrate that the 7.2 mg semaglutide dose provides superior weight reduction compared ...

Semaglutide is the active ingredient in Ozempic, used to treat Type 2 diabetes, and Wegovy, used for weight management, both made by Danish pharmaceutical company Novo Nordisk.

The Food and Drug Administration approved a higher-dose version of a popular class of obesity drugs on Thursday, the latest expansion in a rapidly growing market for weight-loss treatments. The newly ...

The clearance, issued 54 days after an approval submission, gives Novo another chance to claw back market share from Eli Lilly.

Eris Lifesciences on Friday launched generic Semaglutide under the brand 'Sundae' in the country with the molecule behind products like Ozempic, and Wegovy, going off patent in India.      The company ...

Eli Lilly 3rd-generation GLP-1 retatrutide lowers A1C by 1.9% and reduces body weight by 33.3 pounds in phase 3 trial.

The FDA has approved a higher 7.2 mg dose of Novo Nordisk’s Wegovy (Wegovy HD) for chronic weight management in adults with ...

Natco Pharma has launched a new generic semaglutide injection in India. This marks a significant step in making advanced diabetes treatment more accessible. The drug is available at a much lower price ...

Novo Nordisk NVO announced that the FDA has approved Wegovy HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction in the long term. NVO expects to ...

Experimenters hope to harness the powerful effects of medications such as Ozempic and Wegovy at doses smaller than those studied most.

The FDA has approved a new higher-dose version of injectable semaglutide (Wegovy HD, Novo Nordisk) for both weight loss and long-term weight-loss maintenance. The higher dose, 7.2 mg, produced an ...

The FDA approved a higher 7.2 mg dose of injectable semaglutide for adults with overweight and obesity, Novo Nordisk announced. Once-weekly injectable semaglutide 7.2 mg (Wegovy HD, Novo Nordisk) ...